Jeanne M. Schilder

Oncology

550 University Blvd
Indianapolis, IN 46202

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study.

Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study.

Journal: Gynecologic oncology

Published: December 17, 2025

Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study.

Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study.

Journal: Advances in therapy

Published: December 16, 2025

Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US.

Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US.

Journal: Future oncology (London, England)

Published: July 14, 2025

Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer.

Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer.

Journal: Future oncology (London, England)

Published: January 17, 2025

The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

Journal: Cancer

Published: December 27, 2024

Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA study.

Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 29, 2024

Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.

Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.

Journal: Future oncology (London, England)

Published: October 24, 2024

Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study.

Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study.

Journal: Oncology and therapy

Published: September 19, 2024

Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study.

Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 07, 2024

Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe.

Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 20, 2024

Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study.

Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study.

Journal: Oncology and therapy

Published: May 23, 2024

Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study.

Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study.

Journal: Oncology and therapy

Published: February 29, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026